Stock Price
169.43
Daily Change
1.35 0.80%
Monthly
10.35%
Yearly
35.52%
Q4 Forecast
164.30

EPS Reference Time Actual Consensus Previous
2026-10-29 FY2026Q3 PM 2.55 2.23 2.47
2026-08-04 FY2026Q2 PM -6.75 -7.32 2.01
2026-05-07 FY2026Q1 PM 2.03 1.9 1.81
2026-02-10 FY2025Q4 PM 1.86 1.89 1.90
2025-10-30 FY2025Q3 PM 2.47 2.16 2.02



Peers Price Chg Day Year Date
AbbVie 297.62 2.59 0.88% 27.19% Nov/16
Agios Pharmaceuticals 31.59 -0.17 -0.54% -27.63% Nov/13
ALKERMES 47.34 0.31 0.66% 63.02% Nov/16
Alnylam Pharmaceuticals 161.77 -3.27 -1.98% -63.98% Nov/16
Amgen 468.72 3.05 0.65% 37.17% Nov/16
Biogen 253.40 2.92 1.17% 51.24% Nov/13
BioMarin Pharmaceutical 57.23 0.53 0.93% 4.57% Nov/13
Bristol-Myers Squibb 63.17 -0.26 -0.41% 35.41% Nov/16
Coherus Biosciences 0.53 -0.01 -2.41% -55.84% Nov/13
Gilead Sciences 169.43 1.35 0.80% 35.52% Nov/16

Indexes Price Day Year Date
US Index 500 7477 -84.19 -1.11% 12.07% Nov/16
USND 24753 -383.47 -1.53% 9.00% Nov/16
US Index 100 27460 -484.15 -1.73% 10.72% Nov/16

Gilead Sciences traded at $169.43 this Monday November 16th, increasing $1.35 or 0.80 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences gained 10.35 percent. Over the last 12 months, its price rose by 35.52 percent. Looking ahead, we forecast Gilead Sciences to be priced at 164.30 by the end of this quarter and at 153.46 in one year, according to Trading Economics global macro models projections and analysts expectations.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.



News Stream
Gilead Sciences Shares Hit All-time High
Gilead Sciences shares increased to an all-time high of 160.51 USD. Over the past 4 weeks, Gilead Sciences gained 7.25%, and in the last 12 months, it increased 34.39%.
2026-10-15
Gilead Sciences Shares Hit 34-week High
Gilead Sciences shares increased to 156.57 USD, the highest since February 2026. Over the past 4 weeks, Gilead Sciences gained 7.13%, and in the last 12 months, it increased 32.49%.
2026-10-15
Gilead Sciences Shares Hit 6-week Low
Gilead Sciences shares decreased to 142.91 USD, the lowest since August 2026. Over the past 4 weeks, Gilead Sciences lost 2.45%, and in the last 12 months, it increased 25.95%.
2026-10-05